ERAS-801 for Glioblastoma

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Erasca, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial is testing ERAS-801, a new drug for treating brain cancer. It focuses on patients whose brain cancer has returned after treatment. The drug works by blocking signals that help cancer cells grow. Researchers want to find the safest and most effective dose of ERAS-801. ERAs may be useful for treating cancer patients.

Eligibility Criteria

This trial is for adults over 18 with recurrent glioblastoma who can take pills orally and have good organ function. They must be able to consent to the study and follow its procedures. People with allergies to ERAS-801, past EGFR inhibitor treatments for glioblastoma, significant heart disease, active infections needing treatment, or gastrointestinal issues affecting drug absorption cannot join.

Inclusion Criteria

I am 18 years old or older.

My organs are working well.

Willing and able to give written informed consent

+3 more

Exclusion Criteria

I have been treated with an EGFR inhibitor for my brain cancer.

I have stomach or intestine problems that could affect how I absorb pills.

I am currently being treated for an infection.

+5 more

Participant Groups

The trial tests different doses of a new medication called ERAS-801 in patients with recurrent glioblastoma to find the safest and most effective dose level. It also looks at how well it works against tumors and studies how the body processes the drug.

2Treatment groups

Experimental Treatment

Group I: Dose Expansion (Part 2)Experimental Treatment1 Intervention

ERAS-801 will be orally administered at the recommended dose (as determined from Part 1) to study participants with recurrent GBM harboring alterations in EGFR.

Group II: Dose Escalation (Part 1)Experimental Treatment1 Intervention

ERAS-801 will be orally administered to study participants with recurrent GBM in sequential ascending doses until unacceptable toxicity, disease progression, or withdrawal of consent.